Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact‐finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan

摘要

Abstract Hereditary breast and ovarian cancer syndrome (HBOC) is a hereditary tumor that can be definitively diagnosed by detection of germline mutation of the BRCA1 or BRCA2 gene. The HBOC Public Awareness and Management Sub‐committee of the Tumor Committee, Japan Society of Obstetrics and Gynecology carried out a fact‐finding survey on the status of treatment of HBOC in Japan. The directors of medical specialty teaching facilities were notified of the questionnaire by post, with the request for one respondent per facility. The response period was from 8 July 2014 to 31 March 2015. Of the 678 facilities that were asked to compete the questionnaire, 341 (50.3%) responded. The responses are shown in the respective tables. For questions with free responses, similar answers have been grouped together, and the written answers have been freely translated. Based on these results, the Japan Society of Obstetrics and Gynecology considers that the 14 conditions, including consultations by specialist staff, must be met before risk‐reducing salpingo‐oophorectomy is carried out.